Johnson & Johnson reveals the pending settlement of a trio of derivatives lawsuits filed by shareholders seeking to reform the healthcare conglomerate. Johnson & Johnson (NYSE:JNJ) said it’s reached agreements to settle a trio of derivatives lawsuits filed by shareholders seeking to reform the healthcare conglomerate after a spate of damaging recalls across its product portfolio. New Brunswick, N.J.-based Johnson & Johnson revealed the agreements, which must still be approved by the U.S. District Court for New Jersey, in a recent regulatory filing.
